Ne pas distribuer aux fils de presse américains ni diffuser aux États-Unis. LE PROSPECTUS PRÉALABLE DE BASE PEUT ÊTRE CONSULTÉ, ET LE SUPPLÉMENT DE PROSPECTUS PRÉALABLE AUX FINS DU PLACEMENT DANS LE PUBLIC ET TOUTE MODIFICATION DE CES DOCUMENTS POURRONT ÊTRE CONSULTÉS, SUR SEDAR+ DANS LES DEUX JOURS OUVRABLES
SINGAPORE, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Health Information Sharing and Analysis Center (Health-ISAC) is pleased to announce the appointment of Paul Chua as its new Asia Pacific (APAC) Operations Director.
TEL AVIV, Israel, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will present its ongoing transformation and expected growth trajectory through 2030 at the 44th Annual J.P. Morgan Healthcare Conference. Teva’s President and Chief Executive Officer, Richard Francis, will meet with investors and present the Company’s milestones achieved in…
CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025, in line with prior financial guidance.
NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed on behalf of all former stockholders of Smartsheet Inc. (NYSE: SMAR) in connection with the January 2025 sale (the “Merger” or “Buyout”) of Smartsheet to affiliates of…
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with deepening improvements in post-swallow residue and total dysphagic symptom burden as compared to the 12-month follow-up timepoint
